search
Back to results

Use of Polyethylene Glycolic Acid or Tachocomb to Prevent Pancreatic Fistula Following Distal Pancreatectomy

Primary Purpose

Pancreatic Fistula

Status
Completed
Phase
Phase 4
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Tachocomb
Polyglycolic acid (PGA) (Neoveil)
Sponsored by
Seoul National University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Pancreatic Fistula focused on measuring Pancreatic fistula, distal Pancreatectomy

Eligibility Criteria

20 Years - 84 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Expected survival time more than 12 months
  • Patients with at least one of the following pathologic diseases scheduled for elective resection

    • Resectable malignancies of the pancreatic body/ tail
    • Resectable pre-malignant lesions of the pancreatic body/ tail
    • Resectable benign lesion of the pancreatic body/ tail

Exclusion Criteria:

  • Current immunosuppressive therapy
  • Pancreatic atrophy or calcification due to severe pancreatitis
  • Chemotherapy or radiotherapy before operation
  • Severe psychiatric or neurologic diseases
  • Drug- and/or alcohol-abuse according to local standards
  • Participation in another intervention trial with interference of a primary or secondary endpoint of this study
  • Inability to follow the instructions given by the investigator
  • Lack of compliance

Sites / Locations

  • Seoul National University Bundang Hospital
  • Department of Surgery, Seoul National University College of Medicine
  • Severance Hospital
  • Samsung Medical Center
  • Gangnam Severance Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

No Intervention

Arm Label

Tachocomb

PGA

Control

Arm Description

Tachocomb will be applicated on the cut surface of distal pancreatectomy

PGA will be applicated on the cut surface of distal pancreatectomy

No mesh will be applicated on the cut surface of distal pancreatectomy

Outcomes

Primary Outcome Measures

The rate of pancreatic fistula between groups
Pancreatic fistula was defined by criterion of ISGPF, Output through an operatively placed drain or a subsequently placed percutaneous drain, of any measurable volume of drain fluid on or after postoperative day 3, with an amylase content greater than three times the upper normal serum value

Secondary Outcome Measures

Surgery-related risk factor
Amount of intraoperative bleeding, blood transfusion, operative time, operative method with open, laparoscopic, or robotic surgery
disease- associated factors
pancreatic hardness, pathological findings, diameter of main p- duct, and the thickness of pancreas resection area
patient-related risk factors analysis
age, sex, race, comorbidity

Full Information

First Posted
November 21, 2011
Last Updated
June 6, 2016
Sponsor
Seoul National University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT01550406
Brief Title
Use of Polyethylene Glycolic Acid or Tachocomb to Prevent Pancreatic Fistula Following Distal Pancreatectomy
Official Title
Use of Polyethylene Glycolic Acid or Tachocomb to Prevent Pancreatic Fistula Following Distal Pancreatectomy: Prospective Multicenter Randomized Study
Study Type
Interventional

2. Study Status

Record Verification Date
June 2016
Overall Recruitment Status
Completed
Study Start Date
November 2011 (undefined)
Primary Completion Date
April 2015 (Actual)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Seoul National University Hospital

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To date, there has been many methods suggested to reduce pancreatic fistula. But there are no evidence of superiority to the other methods. This study is a multicenter prospective randomized phase III study of use of Tachocomb or Polyethylene Glycolic Acid (PGA) to prevent of pancreatic fistula after distal pancreatectomy.
Detailed Description
Distal pancreatectomy has been called to by various names such as, left-sided pancreatectomy, distal partial pancreatectomy. It is difficult to define which part of the pancreas as distal in exactly, but typically the superior mesenteric vein (SMV) and splenic vein, come to meet portal vein to form the area that covers the pancreas, neck actually based on a relatively thin pancreatic resection area, if left to its distal pancreatic resection is generally defined as that. Indication of distal pancreatectomy in Western countries have been trauma (16%), pancreas cancer (18%), neuroendocrine tumors (14%), chronic pancreatitis (24%), other benign disease (22%) and in Korea, in contrast, disease caused by inflammatory process such as chronic pancreatitis has had relatively low incidence. But the rate of combined resection of distal pancreas at the time of gastric surgery was relatively high. Definitions and names of pancreatic fistula have been reported differently in each center. Heidelberg and Johns Hopkins groups defined pancreatic fistula as drain amylase levels more than three times of normal serum value , and with more than 50mL during 24 hours after postoperative 10 days. German and Italian groups defined that as drain amylase levels more than three times of normal serum value, and with more than 10mL during 24 hours after postoperative 3-4 days. Japanese group defined pancreatic fistula as drain amylase levels more than three times of normal serum value, and with persistent drainage after postoperative 7 days. Lowy et al defined clinically significant pancreatic fistula as 38℃ or more of fever and leukocytosis (> 10,000 cells/mm3), and sepsis associated or necessity of drainage of abdominal fluid. To adjust this various criteria, International Study Group Pancreatic Fistula (ISGPF) 2005 defined pancreatic fistula as drain amylase levels more than three times of normal serum value at the time of postoperative 3 days, and divided severity by 3 category with A to C in accordance with clinical course. As followed previous studies, pancreatic fistula has been one of major postoperative complications (13-64%), which is leading cause of intra-abdominal infections, abscesses, septicemia, wound infection, postoperative bleeding, and malnutrition Risk factors related pancreas fistula have been presented as a disease- associated factors (pancreatic hardness, pathological findings, diameter of main p- duct, and the thickness of pancreas resection area), surgery-related factors (method of pancreas resection, intraoperative blood loss, operative time, blood transfusion during surgery), patient-related factors (age, sex, race, comorbidity) and the experience of surgeon, etc. Based on experience and observation of the above listed risk factors for pancreatic fistula, there has been rarely reported that the incidence of pancreatic fistula was markedly reduced by some kind of methods. As mentioned above, one of the risk factors of pancreatic fistula is operative method or technique. To date, there has been many methods suggested to reduce pancreatic fistula. For example, as dealing with pancreas cut surface, there has been several methods, such as, hand-sewn suture techniques, stapled closure, the use of fibrin glue, the use of mesh. But there are few evidence of superiority to the other methods. Recent retrospective studies suggested the usefulness of mesh that the incidence of pancreatic fistula with mesh (5.6-27%) was lower than without mesh (38.9~42.0%). There are two kind of mesh to use surgical fields, that are PGA and tachocomb. Among that, the methods with PGA has been reported in a few retrospective study. Moreover, there are no report about the effectiveness with Tachocomb. The objective of this prospective multicenter randomized study is to clarify the proper method to reduce pancreatic fistula by PGA or tachocomb.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pancreatic Fistula
Keywords
Pancreatic fistula, distal Pancreatectomy

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
150 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Tachocomb
Arm Type
Active Comparator
Arm Description
Tachocomb will be applicated on the cut surface of distal pancreatectomy
Arm Title
PGA
Arm Type
Active Comparator
Arm Description
PGA will be applicated on the cut surface of distal pancreatectomy
Arm Title
Control
Arm Type
No Intervention
Arm Description
No mesh will be applicated on the cut surface of distal pancreatectomy
Intervention Type
Device
Intervention Name(s)
Tachocomb
Intervention Description
A kind of Mesh: ready-to-use hemostatic agent consisting of a collagen sheet coated on one side with human fibrinogen, bovine thrombin, and bovine aprotinin
Intervention Type
Device
Intervention Name(s)
Polyglycolic acid (PGA) (Neoveil)
Other Intervention Name(s)
Neoveil
Intervention Description
Polyglycolide or Polyglycolic acid (PGA) is a biodegradable, thermoplastic polymer and the simplest linear, aliphatic polyester.
Primary Outcome Measure Information:
Title
The rate of pancreatic fistula between groups
Description
Pancreatic fistula was defined by criterion of ISGPF, Output through an operatively placed drain or a subsequently placed percutaneous drain, of any measurable volume of drain fluid on or after postoperative day 3, with an amylase content greater than three times the upper normal serum value
Time Frame
postoperative 3rd day
Secondary Outcome Measure Information:
Title
Surgery-related risk factor
Description
Amount of intraoperative bleeding, blood transfusion, operative time, operative method with open, laparoscopic, or robotic surgery
Time Frame
intraoperative time
Title
disease- associated factors
Description
pancreatic hardness, pathological findings, diameter of main p- duct, and the thickness of pancreas resection area
Time Frame
intraoperative time, within 1 day after operation
Title
patient-related risk factors analysis
Description
age, sex, race, comorbidity
Time Frame
1 week before the operation

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
84 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Expected survival time more than 12 months Patients with at least one of the following pathologic diseases scheduled for elective resection Resectable malignancies of the pancreatic body/ tail Resectable pre-malignant lesions of the pancreatic body/ tail Resectable benign lesion of the pancreatic body/ tail Exclusion Criteria: Current immunosuppressive therapy Pancreatic atrophy or calcification due to severe pancreatitis Chemotherapy or radiotherapy before operation Severe psychiatric or neurologic diseases Drug- and/or alcohol-abuse according to local standards Participation in another intervention trial with interference of a primary or secondary endpoint of this study Inability to follow the instructions given by the investigator Lack of compliance
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jin- Young Jang, M.D.
Organizational Affiliation
Seoul National University Hospital
Official's Role
Study Chair
Facility Information:
Facility Name
Seoul National University Bundang Hospital
City
Seongnam
State/Province
Bundang-gu
ZIP/Postal Code
463-707
Country
Korea, Republic of
Facility Name
Department of Surgery, Seoul National University College of Medicine
City
Seoul
ZIP/Postal Code
110-744
Country
Korea, Republic of
Facility Name
Severance Hospital
City
Seoul
ZIP/Postal Code
120-752
Country
Korea, Republic of
Facility Name
Samsung Medical Center
City
Seoul
ZIP/Postal Code
130-710
Country
Korea, Republic of
Facility Name
Gangnam Severance Hospital
City
Seoul
ZIP/Postal Code
135-720
Country
Korea, Republic of

12. IPD Sharing Statement

Citations:
PubMed Identifier
27784046
Citation
Jang JY, Shin YC, Han Y, Park JS, Han HS, Hwang HK, Yoon DS, Kim JK, Yoon YS, Hwang DW, Kang CM, Lee WJ, Heo JS, Kang MJ, Chang YR, Chang J, Jung W, Kim SW. Effect of Polyglycolic Acid Mesh for Prevention of Pancreatic Fistula Following Distal Pancreatectomy: A Randomized Clinical Trial. JAMA Surg. 2017 Feb 1;152(2):150-155. doi: 10.1001/jamasurg.2016.3644.
Results Reference
derived
PubMed Identifier
26681272
Citation
Park JS, Lee DH, Jang JY, Han Y, Yoon DS, Kim JK, Han HS, Yoon Y, Hwang D, Kang CM, Hwang HK, Lee WJ, Heo J, Chang YR, Kang MJ, Shin YC, Chang J, Kim H, Jung W, Kim SW. Use of TachoSil((R)) patches to prevent pancreatic leaks after distal pancreatectomy: a prospective, multicenter, randomized controlled study. J Hepatobiliary Pancreat Sci. 2016 Feb;23(2):110-7. doi: 10.1002/jhbp.310. Epub 2016 Jan 19.
Results Reference
derived

Learn more about this trial

Use of Polyethylene Glycolic Acid or Tachocomb to Prevent Pancreatic Fistula Following Distal Pancreatectomy

We'll reach out to this number within 24 hrs